Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial - Curtis, Jeffrey R; Yamaoka, Kunihiro; Chen, Yi-Hsing; Bhatt, Deepak L; Gunay, Levent M; Sugiyama, Naonobu; Connell, Carol A; Wang, Cunshan; Wu, Joseph; Menon, Sujatha; Vranic, Ivana; Gómez-Reino, Juan J (Annals of the rheumatic diseases, 2023)
Keywords: antirheumatic agents; Antirheumatic Agents - therapeutic use; Arteriosclerosis; arthritis, rheumatoid; Arthritis, Rheumatoid - chemically induced; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - epidemiology; Cancer therapies; Cardiovascular disease; Cardiovascular diseases; Drug dosages; Humans; Lung cancer; Lung Neoplasms - chemically induced; Lung Neoplasms - epidemiology; Lymphoma; Malignancy; Medical screening; Melanoma; Patients; Population studies; Pyrroles - adverse effects; Rheumatoid Arthritis; Risk Factors; Skin cancer; Skin Neoplasms; Surveillance; TNF inhibitors; Treatment Outcome; Tumor necrosis factor; tumor necrosis factor inhibitors; Tumor Necrosis Factor Inhibitors - therapeutic use; Tumor necrosis factor-TNF; Tumors; arthritis, rheumatoid; cardiovascular diseases; tumor necrosis factor inhibitors; antirheumatic agents